Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

Via Peters

ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and 75% of Evaluable Patients with Excess Baseline Complement Activity NfL Levels Remained Consistent and Were Comparable to Published Natural […]